You are here

Article Text

Article menu
Download PDFPDF
Editorial
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

https://doi.org/10.1136/heartjnl-2017-312858

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors contributed to the idea, design and analyses of the study and drafted the manuscript. AFS had full access to all of the data and takes responsibility for the integrity of the data presented.

    • Funding AFS is funded by UCLH NIHR Biomedical Research Centre and is a UCL Springboard Population Health Sciences Fellow. ADH is an NIHR Senior Investigator and is funded by the UCL Hospitals NIHR Biomedical Research Centre.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All data are available at: http://www.cochrane.org/CD011748/VASC_pcsk9-inhibitors-prevention-cardiovascular-disease.

    • Collaborators John Overington.

    • Presented at This study and its results were presented at the 2016 Cochrane colloquium in Seoul, South Korea and are published as a Cochrane systematic review and meta-analysis.